Sugi Predict

Sugi Predict / Targets / VKORC1

VKORC1

Vitamin K epoxide reductase complex subunit 1 · Q9BQB6 · VKORC1 on Sugi Atlas →

3,434 patent compounds predicted against VKORC1, 2,227 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3173702 SCHEMBL3173702 0.53 9/20
SCHEMBL1648127 SCHEMBL1648127 0.79 8/20
SCHEMBL1648186 SCHEMBL1648186 0.78 8/20
SCHEMBL3175636 SCHEMBL3175636 0.77 8/20
Dicumarol Dicumarol (SCHEMBL33891) 0.72 8/20
SCHEMBL1648184 SCHEMBL1648184 0.72 8/20
SCHEMBL1648171 SCHEMBL1648171 0.71 8/20
SCHEMBL1649892 SCHEMBL1649892 0.71 8/20
SCHEMBL1649108 SCHEMBL1649108 0.71 8/20
SCHEMBL4959844 SCHEMBL4959844 0.70 8/20
SCHEMBL1649876 SCHEMBL1649876 0.69 8/20
SCHEMBL1649886 SCHEMBL1649886 0.69 8/20
SCHEMBL3177583 SCHEMBL3177583 0.69 8/20
SCHEMBL1649906 SCHEMBL1649906 0.68 8/20
SCHEMBL1648030 SCHEMBL1648030 0.65 8/20
SCHEMBL1649128 SCHEMBL1649128 0.65 8/20
SCHEMBL4958234 SCHEMBL4958234 0.65 8/20
SCHEMBL3157707 SCHEMBL3157707 0.64 8/20
SCHEMBL1647668 SCHEMBL1647668 0.64 8/20
SCHEMBL5155086 SCHEMBL5155086 0.64 8/20

Clinical trials — most relevant to VKORC1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care PHASE4WITHDRAWN
Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy PHASE4COMPLETED
EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin PHASE4COMPLETED
EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon PHASE4COMPLETED
EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol PHASE4COMPLETED
The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. PHASE4UNKNOWN
Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose PHASE3UNKNOWN
Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability? PHASE3COMPLETED
Protocol for Improvement of Therapy With Warfarin PHASE3ENROLLING_BY_INVITATION
Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy PHASE3COMPLETED
Drug Interaction Study of Warfarin and MT-3995 PHASE1COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings nanCOMPLETED
VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management nanUNKNOWN
The Prevalence of Sub Optimal Anti Coagulation nanUNKNOWN
Pharmacogenetics of Acenocoumarol nanCOMPLETED
The Study of Warfarin Maintenance Dose in Chinese Patients nanUNKNOWN
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information nanCOMPLETED
Genotype-Guided Warfarin Therapy Trial nanCOMPLETED
Genetic Response to Warfarin in Healthy Subjects nanCOMPLETED
Warfarin Effects on Male Fertility After Cardiac Surgery nanNOT_YET_RECRUITING
Safer Warfarin Treatment nanSUSPENDED
Evaluating LumiraDx INR Test Accuracy in Patients Taking Phenprocoumon Anticoagulant. nanCOMPLETED
Genetic Determinants of Warfarin Anticoagulation Effect nanUNKNOWN
Pharmacogenetics of Warfarin in Puerto Ricans. nanCOMPLETED
Aortic Calcification and Vitamin K Antagonists nanCOMPLETED
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR nanUNKNOWN
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics nanCOMPLETED
Pharmacogenetic Dosage Algorithm for Acenocoumarol nanCOMPLETED
Evaluation of Primex's PGX Assay to Assess the Clinical Utility of Pharmacogenomics nanUNKNOWN
Gene-guided Warfarin for Anticoagulation Therapy nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a VKORC1 binder may also engage these)

ProteinNameSimilarity
Q9CRC0 — 1.000 Q9CRC0 →
Q6B4J2 — 1.000 Q6B4J2 →
Q6TEK4 — 1.000 Q6TEK4 →
Q6TEK5 — 0.996 Q6TEK5 →
Q6TEK8 — 0.992 Q6TEK8 →
VKORC1L1 Vitamin K epoxide reductase complex subunit 1-like protein 1 0.989 landscape →
Q6TEK3 — 0.989 Q6TEK3 →
O14894 — 0.967 O14894 →
Q49LS7 — 0.966 Q49LS7 →
Q3SZ36 — 0.966 Q3SZ36 →
Q4VV71 — 0.966 Q4VV71 →
Q9WVM4 — 0.965 Q9WVM4 →
Q5Z413 — 0.965 Q5Z413 →
A0A1B0GTI8 — 0.965 A0A1B0GTI8 →
Q8K0H7 — 0.965 Q8K0H7 →
P70245 — 0.965 P70245 →
O42153 — 0.965 O42153 →
Q28GF8 — 0.965 Q28GF8 →
Q91XE8 — 0.964 Q91XE8 →
Q8N2M4 — 0.964 Q8N2M4 →
A8KBG2 — 0.963 A8KBG2 →
Q0DWA9 — 0.963 Q0DWA9 →
Q9D8N3 — 0.963 Q9D8N3 →
A6NC51 — 0.963 A6NC51 →
A6NDP7 — 0.963 A6NDP7 →
Q32L10 — 0.963 Q32L10 →
Q96DZ7 — 0.963 Q96DZ7 →
Q9EQK7 — 0.963 Q9EQK7 →
B2MVP8 — 0.963 B2MVP8 →
Q1KKV8 — 0.963 Q1KKV8 →